Revisiting the complex influences of cannabinoids on motor functions unravels pharmacodynamic differences between cannabinoid agonists

Neuropharmacology

Volumn 59, Issue 6, 2010, Pages 503-510

  Bosier, Barbara ^a   Sarre, Sophie ^b   Smolders, Ilse ^b   Michotte, Yvette ^b   Hermans, Emmanuel ^a   Lambert, Didier M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cannabinoids; Catalepsy; CP 55940; HU 210; Locomotion

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; DEXANABINOL; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG POTENCY; EX VIVO STUDY; IN VIVO STUDY; LATENT PERIOD; LOCOMOTION; MALE; MOTOR PERFORMANCE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; REARING;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CANNABINOIDS; CATALEPSY; CYCLOHEXANOLS; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 77956934156     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.07.005     Document Type: Article

References (54)

1. Adams I.B., Ryan W., Singer M., Thomas B.F., Compton D.R., Razdan R.K., Martin B.R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 1995, 273:1172-1181.
2. Anavi-Goffer S., Fleischer D., Hurst D.P., Lynch D.L., Barnett-Norris J., Shi S., Lewis D.L., Mukhopadhyay S., Howlett A.C., Reggio P.H., Abood M.E. Helix 8 Leu in the CB1 cannabinoid receptor contributes to selective signal transduction mechanisms. J. Biol. Chem. 2007, 282:25100-25113.
3. Baskfield C.Y., Martin B.R., Wiley J.L. Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice. J. Pharmacol. Exp. Ther. 2004, 309:86-91.
4. Bass C.E., Griffin G., Grier M., Mahadevan A., Razdan R.K., Martin B.R. SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study. Pharmacol. Biochem. Behav. 2002, 74:31-40.
5. Bonhaus D.W., Chang L.K., Kwan J., Martin G.R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther. 1998, 287:884-888.
6. Bosier B., Hermans E., Lambert D. Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor. Br. J. Pharmacol. 2008, 155:24-33.
7. Bosier B., Hermans E., Lambert D.M. Concomitant activation of adenylyl cyclase suppresses the opposite influences of CB(1) cannabinoid receptor agonists on tyrosine hydroxylase expression. Biochem. Pharmacol. 2009, 77:216-227.
8. Bosier B., Lambert D.M., Hermans E. Reciprocal influences of CB1 cannabinoid receptor agonists on ERK and JNK signalling in N1E-115 cells. FEBS Lett. 2008, 582:3861-3867.
9. Bosier B., Tilleux S., Najimi M., Lambert D.M., Hermans E. Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line. J. Neurochem. 2007, 102:1996-2007.
10. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.P., Le Fur G., Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 1997, 272:22330-22339.
11. Brown A.J. Novel cannabinoid receptors. Br. J. Pharmacol. 2007, 152:567-575.
12. Burkey T.H., Quock R.M., Consroe P., Ehlert F.J., Hosohata Y., Roeske W.R., Yamamura H.I. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur. J. Pharmacol. 1997, 336:295-298.
13. Compton D.R., Aceto M.D., Lowe J., Martin B.R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 1996, 277:586-594.
14. Compton D.R., Prescott W.R., Martin B.R., Siegel C., Gordon P.M., Razdan R.K. Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol. J. Med. Chem. 1991, 34:3310-3316.
15. Compton D.R., Rice K.C., De Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 1993, 265:218-226.
16. Cosenza M., Gifford A.N., Gatley S.J., Pyatt B., Liu Q., Makriyannis A., Volkow N.D. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse 2000, 38:477-482.
17. Costa B., Colleoni M. SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists. Zhongguo Yao Li Xue. Bao. 1999, 20:1103-1108.
18. Demir R., Leuwer M., de la Rochea J., Krampfl K., Foadi N., Karst M., Dengler R., Haeseler G., Ahrens J. Modulation of glycine receptor function by the synthetic cannabinoid HU210. Pharmacology 2009, 83:270-274.
19. Di Marzo V., Breivogel C.S., Tao Q., Bridgen D.T., Razdan R.K., Zimmer A.M., Zimmer A., Martin B.R. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 2000, 75:2434-2444.
20. Fowler C.J., Gustafsson S.B., Chung S.C., Persson E., Jacobsson S.O., Bergh A. Targeting the endocannabinoid system for the treatment of cancer - a practical view. Curr. Top. Med. Chem. 2010, 10:814-827.
21. Georgieva T., Devanathan S., Stropova D., Park C.K., Salamon Z., Tollin G., Hruby V.J., Roeske W.R., Yamamura H.I., Varga E. Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. Eur. J. Pharmacol. 2008, 581:19-29.
22. Glass M., Northup J.K. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol. Pharmacol. 1999, 56:1362-1369.
23. Govaerts S.J., Hermans E., Lambert D.M. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur. J. Pharm. Sci. 2004, 23:233-243.
24. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 2003, 42:327-360.
25. Gustafsson S.B., Lindgren T., Jonsson M., Jacobsson S.O. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother. Pharmacol. 2009, 63:691-701.
26. Hajos N., Ledent C., Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001, 106:1-4.
27. Harvey D.J., Agurell S. Absorption, distribution, and biotransformation of the cannabinoids. Marijuana and Medicine 1999, Humana Press Inc, Totowa, New Jersey, pp. 91-103.
28. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54:161-202.
29. Jarbe T.U., Andrzejewski M.E., DiPatrizio N.V. Interactions between the CB1 receptor agonist delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol. Biochem. Behav. 2002, 73:911-919.
30. Jarbe T.U., DiPatrizio N.V., Li C., Makriyannis A. The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacol. Biochem. Behav. 2003, 75:809-821.
31. Jarbe T.U., Ross T., DiPatrizio N.V., Pandarinathan L., Makriyannis A. Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats. Pharmacol. Biochem. Behav. 2006, 85:243-252.
32. Lau A.H., Chow S.S. Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells. Eur. J. Pharmacol. 2003, 464:229-235.
33. Lauckner J.E., Hille B., Mackie K. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:19144-19149.
34. Little P.J., Compton D.R., Mechoulam R., Martin B.R. Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs. Pharmacol. Biochem. Behav. 1989, 32:661-666.
35. Martin B.R., Compton D.R., Little P.J., Martin T.J., Beardsley P.M. Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids. NIDA Res. Monogr. 1987, 79:108-122.
36. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 1991, 40:471-478.
37. Martin R.S., Luong L.A., Welsh N.J., Eglen R.M., Martin G.R., MacLennan S.J. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Br. J. Pharmacol. 2000, 129:1707-1715.
38. Martin-Calderon J.L., Munoz R.M., Villanua M.A., del Arco I., Moreno J.L., de Fonseca F.R., Navarro M. Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur. J. Pharmacol. 1998, 344:77-86.
39. Mauler F., Mittendorf J., Horvath E., De Vry J. Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J. Pharmacol. Exp. Ther. 2002, 302:359-368.
40. McMahon L.R., Koek W. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. Eur. J. Pharmacol. 2007, 569:70-76.
41. Mukhopadhyay S., Howlett A.C. Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol. Pharmacol. 2005, 67:2016-2024.
42. O'Sullivan S.E., Tarling E.J., Bennett A.J., Kendall D.A., Randall M.D. Novel time-dependent vascular actions of delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem. Biophys. Res. Commun. 2005, 337:824-831.
43. Oka S., Nakajima K., Yamashita A., Kishimoto S., Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 2007, 362:928-934.
44. Oz M. Receptor-independent effects of endocannabinoids on ion channels. Curr. Pharm. Des. 2006, 12:227-239.
45. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58:389-462.
46. Padwal R.S., Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71-77.
47. Petitet F., Jeantaud B., Bertrand P., Imperato A. Cannabinoid penetration into mouse brain as determined by ex vivo binding. Eur. J. Pharmacol. 1999, 374:417-421.
48. Pistis M., Perra S., Pillolla G., Melis M., Gessa G.L., Muntoni A.L. Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated actions. Neuropharmacology 2004, 46:115-125.
49. Rao G.K., Kaminski N.E. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. J. Pharmacol. Exp. Ther. 2006, 317:820-829.
50. Ryan W., Singer M., Razdan R.K., Compton D.R., Martin B.R. A novel class of potent tetrahydrocannabinols (THCS): 2′-yne-delta 8- and delta 9-THCS. Life Sci. 1995, 56:2013-2020.
51. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., Elebring T., Nilsson K., Drmota T., Greasley P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007, 152:1092-1101.
52. Smith F.L., Fujimori K., Lowe J., Welch S.P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol. Biochem. Behav. 1998, 60:183-191.
53. Sugiura T., Kodaka T., Nakane S., Miyashita T., Kondo S., Suhara Y., Takayama H., Waku K., Seki C., Baba N., Ishima Y. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem. 1999, 274:2794-2801.
54. Wiley J.L., Compton D.R., Dai D., Lainton J.A., Phillips M., Huffman J.W., Martin B.R. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J. Pharmacol. Exp. Ther. 1998, 285:995-1004.